SCHEMBL23212976

SCHEMBL23212976

CC(C)(C)OC(=O)N1CC2(CC(N3CCC(c4cc(F)ccc4O[C@H]4CCOC4)CC3)CO2)C1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 7/20 0.61
CHRM1 P11229 7/20 0.61
CHRM2 P08172 3/20 0.47
CHRM5 P08912 1/20 0.47
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38
ATXN2 Q99700 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4D Q08499 2/20 0.36
ADAM10 O14672 1/20 0.36
GPR119 Q8TDV5 1/20 0.35
HRH3 Q9Y5N1 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4C Q08493 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23212982 1.00 CHRM4 (0.61) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL23212980 1.00 CHRM4 (0.61) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL23230126 1.00 CHRM4 (0.61) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL23230096 0.96 CHRM4 (0.62) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL23230154 0.95 CHRM4 (0.65) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL23230089 0.93 CHRM4 (0.62) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL29871368 0.92 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL29871395 0.91 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL29871410 0.91 CHRM4 (0.53) CHRM4CHRM1CHRM2CHRM5CCNT1
SCHEMBL23230163 0.91 CHRM4 (0.51) CHRM4CHRM1CHRM2CHRM5ATXN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140959-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS AG (CH) 2024-05-02 US disclosed
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-11-21 US disclosed
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-12-29 US disclosed
US-11485742-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2022-11-01 US disclosed
US-20210130365-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2021-05-06 US disclosed
WO-2021070091-A1 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS AG (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485742-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-20240140959-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-20210130365-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.